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Edited by Veli-Pekka LehtoAbstract Platelet-derived growth factor (PDGF) is involved in
megakaryocytopoiesis and is secreted into the culture medium
during megakaryocytic diﬀerentiation of human leukemic cells.
We investigate whether PDGF plays a role in the regulation of
the adapter protein Disabled-2 (DAB2) that expresses abun-
dantly in platelets and megakaryocytes. Western blot analysis
revealed that conditioned medium from 12-O-tetradecanoylphor-
bol-13-acetate (TPA)-treated, megakaryocytic diﬀerentiating
K562 cells upregulated DAB2 expression. DAB2 induction and
megakaryocytic diﬀerentiation was abrogated when cells were
co-treated with the PDGF receptor inhibitor STI571 or when
the conditioned medium was derived from TPA-plus STI571-
treated cells. Although the level of PDGF mRNA was not altered
by STI571, an approximate 44% decrease in PDGF in the con-
ditioned medium was observed. Consistent with these ﬁndings,
interfering PDGF signaling by PDGF neutralization antibody
or dominant negative PDGF receptors attenuated DAB2 expres-
sion. Accordingly, transfection of an expression plasmid encod-
ing secreted PDGF upregulated DAB2. This study shows for
the ﬁrst time that PDGF autocrine signaling regulates DAB2
expression during megakaryocytic diﬀerentiation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Platelet-derived growth factor (PDGF) constitutes a family
of peptide growth factors that includes at least four dimeric
forms, PDGF-AA, -AB, -BB, and -CC [1]. PDGF dimer is
linked together by disulﬁde bonds and activates two speciﬁc
receptors, the PDGF a-receptor (PDGFRa) and the PDGF
b-receptor (PDGFRb). In blood, PDGF expresses abundantly
in megakaryocyte and platelet a-granule. Targeting disruption
of PDGF-B or PDGFRb results in various hematopoietic de-
fects, including microvessel leakage, hemorrhage, microaneu-
rysm formation, anemia, and thrombocytopenia [2,3]. ApartAbbreviations: DAB2, Disabled-2; PDGF, platelet-derived growth
factor; TPA, 12-O-tetradecanoylphorbol-13-acetate
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doi:10.1016/j.febslet.2005.06.080from its pivotal role in thrombosis and hemostasis, PDGF is
a positive regulator for megakaryocytopoiesis. During megak-
aryocytic diﬀerentiation of human leukemic cells, PDGF-A and
PDGF-B are induced through gene activation and are secreted
into the culture medium together with other autocrine regula-
tory factors [4,5]. The conditioned medium retains the ability
to induce megakaryocytic diﬀerentiation [6], with PDGF sig-
naling mediates the expression of megakaryocyte-associated
transcription factors NF-E2, GATA-1, and c-FOS [7]. PDGF
is thus considered as one of the megakaryocytic lineage deter-
mination factors present in the conditioned medium.
Disabled-2 (DAB2) is an adapter protein that is implicated in
growth factor signaling [8,9], endocytosis [10–12], and cell
adhesive function [13,14]. During in vitro megakaryocytic dif-
ferentiation of human leukemic cells and human umbilical cord
blood CD34+ hematopoietic stem cells, DAB2 is upregulated
and acts as a negative regulator in integrin a IIbb3-mediated
ﬁbrinogen adhesion and cell signaling [13,15,16]. DAB2 is also
induced during visceral endoderm and gastrointestinal develop-
ment and retinoic acid-induced F9 cell diﬀerentiation [17–19].
Of these diﬀerentiation models, DAB2 is mainly regulated at
the transcriptional level. However, our previous study [16] in
comparing the extent of DAB2 mRNA and protein expression
during megakaryocytic diﬀerentiation of K562 cells implicates
the presence of an additional level of regulation in the control
of DAB2 gene expression that has not yet been characterized.
With the tight association between DAB2 expression and
megakaryocytic diﬀerentiation and the presence of megakaryo-
cytic lineage determination factors in the conditioned medium,
we address whether the autocrine regulatory factors plays a role
in DAB2 expression. In this study, we report that the condi-
tionedmedium frommegakaryocytic diﬀerentiating cells retains
the ability to induce DAB2 and implicates a link betweenDAB2
expression and autocrine signaling. Through molecular target-
ing approaches using PDGF receptor inhibitor STI571 [20],
dominant negative PDGF receptors and expression of recombi-
nant PDGF,we further demonstrate that the autocrine signaling
of PDGF plays a crucial role in the regulation of DAB2 expres-
sion mainly through a non-transcriptional control mechanism.2. Materials and methods
2.1. Materials
The anti-b-actin antibody and TPA were purchased from Sigma
Chemical Co. (St. Louis, MO). The anti-DAB2 antibody p96 was
purchased from BD Transduction Laboratories (San Jose, CA). Theblished by Elsevier B.V. All rights reserved.
Fig. 1. TPA-conditioned medium induces DAB2 expression. (A,B)
K562 cells (5 · 104/ml) were treated with TPA (T, 10 ng/ml) or solvent
control ethanol (E) for the indicated time (panel A). Alternatively,
K562 cells were incubated with E or T for the indicated time and the
medium was replaced by fresh RPMI 1640 medium without TPA for a
total of 72 h (panel B). Conditioned medium was then collected and
applied to exponential growing K562 cells (1.5 · 104/ml) for 48 h. Total
cell lysates were collected and subjected to Western blot analysis with
anti-p96 (DAB2) antibody. The expression of b-actin was used as a
control for equal protein loading. Essentially similar results were
obtained in 3 independent experiments.
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from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-p42/p44
MAPK and phospho-p42/p44 MAPK antibodies were purchased from
New England Biolab (Beverly, MA). Quantikine human PDGF-BB
immunoassay and the anti-PDGF neutralization antibody were from
R&D Systems Inc. (Minneapolis, MN). The STI571 (Gleevec) is the
product of Novartis Pharma AG (Basel, Switzerland). The 2· SYBR
Green I PCR master mix was purchased from Applied Biosystems
(Foster City, CA). The kinase-inactive K627A PDGFRa and K634A
PDGFRb expression plasmids [21] were a kind gift from Dr. Carl-
Henrik Heldin (Ludwig Institute for Cancer Research, Uppsala, Swe-
den). The truncated PDGFRa expression plasmid [22] was a kind gift
from Dr. Andrius Kazlauskas (The Schepens Eye Research Institute,
Harvard Medical School, Boston, MA).
2.2. Plasmid construction
To generate pcDNA3-D-PDGFRa, a 2.0-kb NotI–ApaI DNA frag-
ment corresponding to the truncated PDGFRa in pLXSN vector [22]
was subcloned into the pcDNA3 expression vector. To construct pSec-
Tag2A-PDGFB, PDGF-B cDNA was obtained from K562 cells by
RT-PCR using the primer set PDGFB-F (5 0-AAGCTTTCTGG-
GTTCCCTGACCAT-3 0) and PDGFB-R (5 0-GGATCCTCGAGGC-
TCCAAGGGT-3 0). The full-length PDGF-B cDNA was then
subcloned into the BamHI–HindIII sites of the pSecTag2A expression
vector (Invitrogen).
2.3. Cell culture, conditioned medium collection, transient transfection,
and Western blot analysis
K562 and OEC-M1 cells were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (FBS) and antibiotics. The conditioned
medium was obtained from the supernatant of K562 cells with the indi-
cated treatment after centrifugation at 1500 rpm for 5 min. Transient
transfection, preparation of total cell lysates, and Western blot analysis
were performed as described previously [13].
2.4. Analysis of CD61 expression by ﬂow cytometry
K562 cells were collected and washed by FABS buﬀer (1· PBS, 1%
FBS, and 0.1% NaN3). The CD61 mouse monoclonal antibody (2 lg/
ml) was added to the cell suspension followedby incubationwith ﬂuores-
cein isothiocyanate-conjugated goat anti-mouse antibody (0.4 lg/ml).
After several washes with the FABS buﬀer, K562 cells were subjected
to ﬂow cytometric analysis with FACSCAN and the data were analyzed
using the CellQuest software (Becton Dickinson, San Jose, CA).
2.5. Real-time quantitative RT-PCR
The one-step real-time quantitative RT-PCR was performed using
the GenAmp 5700 Sequence Detection System (Applied Biosystems,
Foster City, CA). Brieﬂy, 300 ng of total RNA was added into a reac-
tion mixture containing 25 ll of 2· SYBR Green I PCR master mix,
1.25 ll of 40· reverse transcriptase mixture, 1 ll of forward primer
Dab2-F (100 nM, 5 0-AGTGAGGCCCTAAGGATTCTAGATGAC-
CAAACTA-3 0), and 1 ll of reverse primer Dab2-R (100 nM, 5 0-CAG-
GATATCTTTGCTTTCTGTTGGACTATTTAGGTC-3 0) in a ﬁnal
volume of 50 ll. The condition for RT-PCR was 1 cycle of 48 C for
30 min, 1 cycle of 95 C for 10 min, and 40 cycles of 95 C for 15 s
and 60 C for 1 min. The cycle threshold value (CT) was used to assess
the quantity of target gene. The relative fold diﬀerence for the expres-
sion of DAB2 mRNA was normalized by the expression of b-actin and
was determined using the value of 2DDCT.
2.6. Luciferase activity assay
The K562 cells (4 · 105) were transiently transfected with 200 ng of
DAB2 promoter ﬁreﬂy luciferase reporter construct phDab2-luc [16]
and 2 ng of Renilla luciferase expression plasmid pRL-TK. After indi-
cated treatment, the cell lysates were subjected to luciferase activity as-
say according to the manufacturers instructions. The ﬁreﬂy luciferase
activity was normalized by the Renilla luciferase activity in each indi-
vidual sample.
2.7. PDGF quantiﬁcation
The human PDGF-BB immunoassay (R&D Systems Inc.) was used
to quantify the amount of PDGF in the conditioned medium. Brieﬂy,
100 ll of PDGF standard or sample medium was mixed with 100 ll ofassay diluent buﬀer. The mixture was then added into a 96-wells plate
that was pre-coated with PDGF-Rb/Fc chimera. Following incubation
with the substrate solution, the stop solution was added and the OD450
was determined using a microplate reader.
2.8. Neutralization of PDGF activity
The PDGF activity in the conditioned medium was neutralized by
incubating the medium with anti-PDGF neutralization antibody or
control IgG antibody for 30 min. The medium was then used to culture
exponential growing K562 cells to determine the eﬀect of PDGF on
DAB2.
2.9. Establishment of dominant negative PDGFRa stable cell lines
K562 cells were transfected with 6 lg of the kinase-inactive K627A
PDGFRa or the truncated PDGFRa (pcDNA3-D-PDGFRa) expres-
sion plasmids. After neomycin selection (400 lg/ml) for 1 month, the
stable cell lines expressing kinase-inactive or truncated PDGFRa were
identiﬁed by Western blot analysis using anti-PDGFRa antibody.3. Results
3.1. TPA-conditioned medium induces DAB2 expression and
megakaryocytic diﬀerentiation
Previous studies have shown that the conditioned medium
from TPA-treated K562 cells mimics the eﬀect of TPA and
induces integrin b3 expression and morphological changes
associated with megakaryocytic diﬀerentiation. To determine
whether the conditioned medium modulates DAB2 expres-
sion, 1–3 days TPA-conditioned medium was collected and
applied to the exponential growing K562 cells. Western blot
analysis revealed that DAB2 was induced with maximum
induction by the medium that has been ‘‘conditioned’’ for
72 h (Fig. 1A). The cells also demonstrated a typical diﬀer-
entiation phenotype with the characteristics of cell enlarge-
ment, decrease in N/C ratio, and nucleus with multiple
lobes (data not shown). As a control, the conditioned med-
ium derived from the cells treated with solvent control eth-
anol had no eﬀect on DAB2 expression and megakaryocytic
diﬀerentiation.
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TPA carryover, we modiﬁed the way for conditioned medium
preparation in the following experiment. At 6, 12, and 24 h
after TPA treatment, the medium was removed and replaced
by fresh medium without TPA. The conditioned medium
was then collected at 72 h after initial TPA treatment and
applied to exponential growing K562 cells. Western blot anal-
ysis revealed that DAB2 was induced to the level comparable
to the medium that has been conditioned for 72 h (e.g., treat-
ment for 72 h without removal of TPA) (Fig. 1B). These results
rule out TPA carryover as the cause of DAB2 induction and
implicate the presence of soluble DAB2 regulator(s) in the
TPA-conditioned medium.Fig. 2. STI571 inhibits DAB2 expression and megakaryocytic diﬀerentiatio
dependent manner. K562 cells (5 · 104/ml) were pretreated with the indicated
TPA (T, 10 ng/ml) or solvent control ethanol (E, 0.01%). Total cell lysates w
integrin b3 antibodies. The expression of b-actin was used as a control for e
DAB2 expression. Either general K562 cell culture medium or TPA-conditio
cells for 72 h, in the presence of 100 nM STI571 (S), 10 ng/ml TPA (T), or solv
Western blot analysis with anti-p96 (DAB2) and anti-b-actin antibodies. C. E
cells (5 · 104/ml) were treated with vehicle ethanol, TPA, or TPA + STI571 (1
by real-time RT-PCR using 300 ng total RNA and was normalized by the lev
promoter activity. The K562 cells (4 · 105) were transfected with phDAB2-lu
by the DMRIE-C transfection reagent. After treatment with ethanol (0.01%),
were collected for luciferase activity assay using the dual-luciferase reporter as
luciferase activity and the normalized activity for the ethanol-treated control g
assays in a representative experiment. Similar results were obtained in three
CD61 expression and cell morphology. K562 cells were treated with ethano
performed to detect the megakaryocytic diﬀerentiation surface marker CD61
Liu stain reagents, and observed by light microscopy. A typical ﬁeld w
TPA + STI571, respectively (panel F).3.2. STI571 inhibits TPA- and conditioned medium-induced
DAB2 expression and megakaryocytic diﬀerentiation
PDGF is involved in megakaryocytopoiesis and is secreted
into the culture medium during megakaryocytic diﬀerentiation
of human leukemic cells. We co-treated K562 cells with TPA
and PDGF signaling inhibitor STI571 to investigate whether
PDGF plays a role in the regulation of DAB2. At the concen-
trations between 0.01 and 1 lM, STI571 inhibited DAB2
expression in a dose-dependent manner. More than 80% of
DAB2 expression was inhibited by 1 lM of STI571 in both
K562 cells (Fig. 2A) and megakaryocytic cell line HEL (data
not shown). The conditioned medium-induced DAB2 expres-
sion was also suppressed by STI571 (Fig. 2B). Because then. (A) STI571 inhibits DAB2 and integrin b3 expression in a dose-
concentrations of STI571 for 15 min followed by 48 h treatment with
ere subjected to Western blot analysis with anti-p96 (DAB2) and anti-
qual protein loading. B. STI571 inhibits conditioned medium-induced
ned medium was collected and applied to exponential growing K562
ent vehicle control (E). Total cell lysates were collected and subjected to
ﬀect of STI571 on TPA-induced DAB2 mRNA expression. The K562
00 nM) for 48 h. The expression level of DAB2 mRNA was determined
els of b-actin mRNA. D. STI571 does not inhibit TPA-induced DAB2
c (200 ng) and the Renilla luciferase expression plasmid pRL-TK (2 ng)
TPA (10 ng/ml), and TPA + STI571 (100 nM) for 24 h, the cell lysates
say system. The DAB2 promoter activity was normalized by the Renilla
roup was arbitrary set as 1. The data represent the mean ± S.E. of three
independent experiments. E and F. Eﬀects of STI571 on TPA-induced
l, TPA, and TPA plus STI571 for 48 h. Flow cytometric analysis was
(panel E). Aliquots of the cell suspension were cytospin, stained with
as shown for K562 cells treated with ethanol (control), TPA, and
Fig. 3. STI571 inhibits DAB2 induction and PDGF secretion. K562
cells were treated with ethanol (E, 0.01%), TPA (T, 10 ng/ml) or TPA
plus STI571 (T + S) for 72 h. The conditioned medium was collected
and applied to the exponential growing K562 cells for 24 and 48 h.
Total cell lysates were subjected to Western blot analysis with anti-p96
(DAB2) and anti-b-actin antibodies (panel A). On the other hand, the
supernatants were collected at 72 h after culture and the concentration
of PDGF in the culture medium was quantiﬁed by the human PDGF-
BB immunoassay (panel B). The data represent the mean ± S.E. of
three assays in a representative experiment. Similar results were
obtained in two independent experiments.
Fig. 4. PDGF neutralization antibody inhibits DAB2 expression. A
and B. TPA-conditioned medium from K562 cells was preincubated
with the indicated concentrations of PDGF neutralization antibody or
IgG control antibody for 30 min. Then exponential growing K562 cells
(8 · 104/ml) were cultured with the pre-treated conditioned medium for
24 h. Total cell extracts were collected and subjected to Western blot
analysis with anti-p96 (DAB2) (panel A), anti-phospho-p42/p44-
MAPK and anti-p42/p44-MAPK (panel B) antibodies. The expression
of b-actin was used as the control of equal protein loading.
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95%, it ruled out non-speciﬁc cellular toxicity as the cause
for the decrease in DAB2.
Whether STI571 aﬀects DAB2 transcription was determined
by both real-time RT-PCR and promoter activity analysis.
TPA induced a 12-fold increase in DAB2 mRNA. In the pres-
ence of STI571, a moderate 30% decrease in TPA-induced
DAB2 mRNA was observed (Fig. 2C). To conﬁrm this ﬁnding,
we transfected phDab2-luc, a TPA-responsive DAB2 pro-
moter luciferase reporter construct, into K562 cells followed
by the indicated treatment (Fig. 2D). Consistent with the
results of real-time RT-PCR, TPA induced approximate 15-
fold increase in phDab2-luc activity and the induction was
not signiﬁcantly altered by STI571. With the distinct extent
of inhibition in DAB2 mRNA and protein, these data impli-
cate that post-transcriptional control may be involved in
STI571-mediated inhibition of DAB2 expression.
In addition to modulate DAB2, integrin b3 expression was
also diminished by STI571 (Fig. 2A). To elucidate the eﬀect
of STI571 on megakaryocytic diﬀerentiation, ﬂow cytometric
analysis was performed to detect the expression of megakary-
ocytic diﬀerentiation surface marker CD61. Our results
revealed that CD61 was reduced to 23% for TPA/STI571-trea-
ted cells compared to 40% for TPA-treated cells (Fig. 2E).
Accordingly, the typical phenotypes of megakaryocytic diﬀer-
entiation were less prominent in the TPA/STI571-treated cells
(Fig. 2F). These results indicate that sub-apoptotic concentra-
tion of STI571 also impedes megakaryocytic diﬀerentiation of
K562 cells.
3.3. STI571 reduces PDGF secretion into the culture medium
To investigate whether STI571 mediates its eﬀect by modu-
lating autocrine signaling, the conditioned medium from
TPA/STI571-treated cells was collected at 72 h after treatment
and applied to the exponential growing K562 cells. As shown
in Fig. 3A, this type of conditioned medium did not induce
DAB2 to the level obtained by the TPA-conditioned medium,
suggesting that the putative secreted DAB2 regulator is altered
by STI571 qualitatively or quantitatively. Based on the fact
that PDGF is present in the TPA-conditioned medium and
STI571 is a potent PDGFR inhibitor, we quantify the amount
of PDGF-BB, a ligand that activates both PDGFRa and
PDGFRb, in the conditioned medium. An approximate 44%
decrease in PDGF-BB was observed for the TPA/STI571-trea-
ted cells (86 pg/ml), in comparison to the TPA-treated cells
(153 pg/ml) (Fig. 3B). The decrease in PDGF was not due to
the change of PDGF gene expression, because STI571 did
not alter PDGF-A and PDGF-B mRNA expression (data
not shown). These results indicate that STI571 modulates the
quantity of PDGF in the conditioned medium during megak-
aryocytic diﬀerentiation.
3.4. PDGF autocrine signaling regulates DAB2 expression
To elicit whether there is a link between PDGF autocrine
signaling and DAB2 expression, the anti-PDGF neutralization
antibody that recognizes PDGF A and B chains and blocks
PDGF receptor activation was added into the TPA-condi-
tioned medium. Western blot analysis revealed that, when
applying to the exponential growing K562 cells, this type of
conditioned medium attenuated its eﬀect on DAB2 induction
in a dose-dependent manner (Fig. 4A). As a control, the IgG
control antibody had no eﬀect on DAB2 expression. Todemonstrate that PDGF signaling is modulated by the neutral-
ization antibody, we used anti-phospho-MAPK antibody to
analyze one of the PDGF downstream eﬀectors, MAPK acti-
vation [21]. As shown in Fig. 4B, MAPK activation is inhibited
by the PDGF neutralization antibody but not the IgG control
antibody, indicating the blockage of PDGF signaling.
To conﬁrm the involvement of PDGF signaling in the regu-
lation of DAB2 expression, the K627A (am) and truncated (at)
forms of dominant negative PDGFRa and K634A (bm) form
of dominant negative PDGFRb were used in the following
study. These constructs have been shown previously as a
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tive PDGFR [21,22]. Transient transfection of these plasmids
increased in PDGFR expression, most prominent in TPA-trea-
ted cells, as demonstrated by Western blot analysis with the
anti-PDGFRa and anti-PDGFRb antibodies (Fig. 5A). With
approximate 50% transfection eﬃciency, TPA-mediated
DAB2 induction was diminished by cotransfection of bm with
either am or at (Fig. 5B). As a control, the cells transfected with
wild-type PDGFRa (awt) and PDGFRb (bwt) had comparable
DAB2 expression as the vector-transfected cells. Using the
K562 stable cell lines expressing at or am, we found that block-
age of PDGFRa alone is suﬃcient to inhibit TPA-mediated
DAB2 induction (Fig. 5C). These data reveal the critical role
of PDGF signaling in DAB2 expression during megakaryocy-
tic diﬀerentiation of K562 cells.
To further elucidate that DAB2 expression is regulated by
the autocrine PDGF signaling, we transiently transfected
K562 cells with pSecTag2A-PDGFB that produced secreted
recombinant PDGF-BB due to the fusion of a murine Igj-
chain V-J2-C signal peptide at the N-terminus of PDGF-BFig. 5. PDGF autocrine signaling regulates DAB2 expression. A. Expressi
control (V), wild type PDGFRa (awt) and PDGFRb (bwt), and dominant neg
lg) were transiently transfected into K562 cells (2 · 106). After the indicated
Western blot analyses with the anti-PDGFRa and anti-PDGFRb antibodie
mediated DAB2 expression. K562 cells were transiently transfected with pcD
cells (panel B) and K562 cells stably expressing pcDNA3 vector, am, and at (p
(E, 0.01%), respectively. Total cell lysates were then collected and subjecte
antibodies. D. PDGF up-regulates DAB2 expression. The vector control or
transfected into K562 and OEC-M1 cells. At 48 h after the indicated treatmen
anti-p96 (DAB2) antibody. The expression of b-actin was used as the controcDNA sequences. Accordingly, we detected a signiﬁcant in-
crease in PDGF-BB (112 pg/ml) in the culture medium. Of
these transfected cells, DAB2 was upregulated simultaneously
with the increase in PDGF-BB. The induction of DAB2 was
more prominent when K562 cells were treated with TPA
(Fig. 5D). The PDGF-mediated DAB2 up-regulation was also
observed in an oral cancer, non-hematopoietic cell line OEC-
M1, indicating that the eﬀect of PDGF on DAB2 gene is not
cell type-speciﬁc. Together, these data strengthen the notion
that PDGF is a positive regulator of DAB2 gene expression.4. Discussion
During megakaryocytic diﬀerentiation of K562 cells, both
PDGF-A and PDGF-B polypeptides are induced by TPA
through gene activation. Following secretion into the medium,
PDGF-A and PDGF-B form homodimer or heterodimer and
elicit autocrine eﬀects on the culture cells through bind-
ing and activation of the membrane protein tyrosine kinaseon levels of various PDGFRa and PDGFRb constructs. The vector
ative PDGFRa (am and at) and PDGFRb (bm) expression plasmids (6
treatment for 24 h, total cell lysates were collected and subjected to
s, respectively. B and C. Dominant negative PDGFR reduced TPA-
NA3 vector control, awt + bwt, am + bm, and at + bm. These transfected
anel C) were treated with TPA (T, 10 ng/ml) or solvent control ethanol
d to Western blot analyses with anti-p96 (DAB2) or anti-PDGFRa
the PDGF-B expression plasmid pSec-Tag2A-PDGFB was transiently
t, cell lysates were collected and subjected to Western blot analysis with
l of equal protein loading for each assay.
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through PI3 kinase, Ras/MAPK, and PLCc pathways that
eventually result in a biological response to aﬀect cell prolifer-
ation and diﬀerentiation [23]. In this study, PDGF is unveiled
for the ﬁrst time as a novel DAB2 regulator. This conclusion is
supported by the ﬁndings that PDGF neutralization antibody,
PDGFR inhibitor STI571 and dominant negative PDGFR
could interfere PDGF signaling and inhibit TPA- and condi-
tioned medium-mediated DAB2 upregulation. To further sup-
port this notion, we found that expression of recombinant
PDGF augments DAB2 induction in megakaryocytic diﬀeren-
tiating cells.
Multiple levels of regulation are involved in the control of
DAB2 expression. Activation of p42/p44-MAPK regulates
DAB2 transcriptional activity during megakaryocytic diﬀeren-
tiation [16]. In visceral endoderm and gastrointestinal develop-
ment, the transcription factors GATA-4, GATA-5, and
GATA-6 are the primary positive regulators for DAB2 expres-
sion [17,18]. In macrophage, PU.1 and interferon consensus se-
quence binding protein are the positive and negative regulator
of DAB2 transcription, respectively [14]. Through microarray
analysis, DAB2 is identiﬁed as a target gene of RARb2 during
retinoic acid-induced diﬀerentiation of F9 cells [19], VHL in
the hypoxic response pathway [24], and GATA-3 during
mouse embryonic development [25]. In this study, interference
of PDGF signaling has only moderate eﬀect on DAB2 mRNA
expression and promoter activity, implicating that PDGF may
elicit its activity at the post-transcriptional or translational
level. Hence, PDGF-mediated cell signaling and regulation
represent an additional mechanism for controlling DAB2
expression during megakaryocytic diﬀerentiation. Such means
of regulation may augment the level of protein expression and
sustain DAB2 expression in the megakaryocytic diﬀerentiating
cells. Similar regulatory mechanism has been shown previously
for the expression of SCL, AML1/RUNX1 and prostaglandin
endoperoxide H synthase-1 proteins associated with megak-
aryocytic diﬀerentiation [26–28]. It is noted that the majority
of those mRNAs under translational regulation have long 5 0-
untranslated regions (UTR) with structured regions which
inhibit the scanning mechanisms of translation. Prediction of
the DAB2 mRNA 5 0-UTR folding structure with the RNA
mfold version 2.3 server software from the Bioinformatic Cen-
ter at Rensselaer and Wadsworth [29] reveals three obvious
stem-loops with a signiﬁcant GC pairing. Whether these
stem-loop structures are important in the translational regula-
tion of DAB2 by PDGF requires further analysis.
Apart from the eﬀects onDAB2, the receptor protein tyrosine
kinase inhibitor STI571 also inhibits megakaryocytic diﬀerenti-
ation. Previous study has demonstrated that STI571 aﬀected the
development and function of dendritic cells generated from
CD34+ peripheral blood progenitor cells [30]. The in vitro
development of the monocyte/macrophage lineage from normal
human bone marrow progenitors was also inhibited by STI571,
whereas neutrophil and eosinophil development was less af-
fected [31]. The STI571-induced apoptosis and the inhibition
of c-Kit activity did not account for its eﬀect on cell diﬀerentia-
tion [30,31]. STI571 may therefore have an inhibitory activity
for other kinase(s) that play a role in hematopoietic cell diﬀer-
entiation. We reveal in this study that inhibition of PDGF sig-
naling accounts for the eﬀect of STI571 on megakaryocytic
diﬀerentiation. These results conﬁrm previous observation that
recombinant PDGF signiﬁcantly enhances megakaryocyte col-ony formation in a dose-dependent manner [32] and further
implicates a role of PDGF in megakaryocytopoiesis.
In summary, this study shows for the ﬁrst time that PDGF
autocrine signaling is a positive regulator for DAB2 expression
and megakaryocytic diﬀerentiation. The present study further
suggests that there is interplay between DAB2 expression,
MAPK activation, autocrine PDGF signaling and megakaryo-
cytopoiesis. Apparently, such information leads us for a better
understanding of how DAB2 is regulated during megakaryo-
cytic diﬀerentiation.
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